Tag: Resverlogix

Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

CALGARY, Alberta, March 27, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed a ninth planned safety review for the Company’s Phase 3, BETonMACE trial for high-risk cardiovascular disease patients and recommended the study continue without modification. The […]

Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

CALGARY, Alberta, Nov. 28, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone downregulates factors and pathways associated with vascular calcification” in Atherosclerosis, the official peer-reviewed scientific journal of the European Atherosclerosis Society. “Apabetalone and its unique mechanism […]

Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences

CALGARY, Alberta, Oct. 22, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announced today its participation at premier conferences including the American Society of Nephrology (ASN) Kidney Week 2018, Clinical Trials on Alzheimer’s Disease (CTAD) 2018 and the American Heart Association (AHA) Scientific Sessions 2018. Through […]

Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

CALGARY, Alberta, Aug. 22, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced it is supporting a satellite symposium on August 25th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics? Satellite Symposium Agenda 15:30 – 15:35 (local […]

Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone

CALGARY, Alberta,, Aug. 07, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced  that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 BETonMACE trial in high-risk cardiovascular disease (CVD) patients has completed a seventh planned safety review and recommended that the […]

Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial

CALGARY, July 10, 2017 /PRNewswire/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced  that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease (“CVD”) and type 2 diabetes mellitus (“DM”). On July 8, 2015, Resverlogix and […]